{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T23:48:36Z","timestamp":1789084116003,"version":"build-2803163510"},"reference-count":56,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education","award":["NRF-2021R1I1A1A01050861"],"award-info":[{"award-number":["NRF-2021R1I1A1A01050861"]}]},{"name":"Ministry of Education","award":["NRF- 2015M2B2A4031262"],"award-info":[{"award-number":["NRF- 2015M2B2A4031262"]}]},{"DOI":"10.13039\/501100014188","name":"Nuclear Research &amp; Development Program","doi-asserted-by":"publisher","award":["NRF-2021R1I1A1A01050861"],"award-info":[{"award-number":["NRF-2021R1I1A1A01050861"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Nuclear Research &amp; Development Program","doi-asserted-by":"publisher","award":["NRF- 2015M2B2A4031262"],"award-info":[{"award-number":["NRF- 2015M2B2A4031262"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Combining standard surgical procedures with personalized chemotherapy and the continuous monitoring of cancer progression is necessary for effective NSCLC treatment. In this study, we developed liposomal nanoparticles as theranostic agents capable of simultaneous therapy for and imaging of target cancer cells. Copper-64 (64Cu), with a clinically practical half-life (t1\/2 = 12.7 h) and decay properties, was selected as the radioisotope for molecular PET imaging. An anti-epidermal growth factor receptor (anti-EGFR) antibody was used to achieve target-specific delivery. Simultaneously, the chemotherapeutic agent doxorubicin (Dox) was encapsulated within the liposomes using a pH-gradient method. The conjugates of 64Cu-labeled and anti-EGFR antibody-conjugated micelles were inserted into the doxorubicin-encapsulating liposomes via a post-insertion procedure (64Cu-Dox-immunoliposomes). We evaluated the size and zeta-potential of the liposomes and analyzed target-specific cell binding and cytotoxicity in EGFR-positive cell lines. Then, we analyzed the specific therapeutic effect and PET imaging of the 64Cu-Dox-immunoliposomes with the A549 xenograft mouse model. In vivo therapeutic experiments on the mouse models demonstrated that the doxorubicin-containing 64Cu-immunoliposomes effectively inhibited tumor growth. Moreover, the 64Cu-immunoliposomes provided superior in vivo PET images of the tumors compared to the untargeted liposomes. We suggest that nanoparticles will be the potential platform for cancer treatment as a widely applicable theranostic system.<\/jats:p>","DOI":"10.3390\/ijms25031813","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T09:24:08Z","timestamp":1706865848000},"page":"1813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of PET Radioisotope Copper-64-Labeled Theranostic Immunoliposomes for EGFR Overexpressing Cancer-Targeted Therapy and Imaging"],"prefix":"10.3390","volume":"25","author":[{"given":"Hwa Yeon","family":"Jeong","sequence":"first","affiliation":[{"name":"Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea"},{"name":"Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Jae","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-099X","authenticated-orcid":false,"given":"Min Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-ho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Jung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheulhee","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Ho","family":"Song","sequence":"additional","affiliation":[{"name":"Division of RI-Convergence Research, Korea Institute of Radiological and Medical Science, Seoul 01812, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-7380","authenticated-orcid":false,"given":"Tae Sup","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of RI-Convergence Research, Korea Institute of Radiological and Medical Science, Seoul 01812, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Serk","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biomedical Laboratory Science, Yonsei University, Wonju 26493, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: Current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.suc.2021.12.001","article-title":"Lung Cancer: Epidemiology and Screening","volume":"102","author":"Oliver","year":"2022","journal-title":"Surg. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.lungcan.2019.09.017","article-title":"Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)","volume":"137","author":"Gelatti","year":"2019","journal-title":"Lung Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.21037\/tlcr-21-197","article-title":"Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV","volume":"10","author":"Brueckl","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semcancer.2020.07.009","article-title":"Precision medicine in non-small cell lung cancer: Current applications and future directions","volume":"84","author":"Yang","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/s41578-020-00269-6","article-title":"Targeted drug delivery strategies for precision medicines","volume":"6","author":"Manzari","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1021\/acsbiomaterials.3c00510","article-title":"Engineered Liposomes in Interventional Theranostics of Solid Tumors","volume":"9","author":"Kommineni","year":"2023","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"119314","DOI":"10.1016\/j.ijpharm.2020.119314","article-title":"Recent advances in theranostic polymeric nanoparticles for cancer treatment: A review","volume":"582","author":"Indoria","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100381","DOI":"10.1016\/j.mtchem.2020.100381","article-title":"Inorganic hybrid nanoparticles in cancer theranostics: Understanding their combinations for better clinical translation","volume":"18","author":"Shetty","year":"2020","journal-title":"Mater. Today Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2014The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4580","DOI":"10.4049\/jimmunol.160.9.4580","article-title":"Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: Cationic lipid complexes","volume":"160","author":"Freimark","year":"1998","journal-title":"J. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0005-2736(92)90084-Y","article-title":"In vitro cytotoxicity of liposome-encapsulated doxorubicin: Dependence on liposome composition and drug release","volume":"1109","author":"Horowitz","year":"1992","journal-title":"Biochim. Biophys. Acta (BBA) Biomembr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00411106","article-title":"Control of in vitro cytotoxicity of positively charged liposomes","volume":"95","author":"Panzner","year":"1979","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0009-3084(93)90070-J","article-title":"Toxicity screening of liposomes","volume":"64","author":"Parnham","year":"1993","journal-title":"Chem. Phys. Lipids"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.nano.2014.08.004","article-title":"In vivo toxicity of cationic micelles and liposomes","volume":"11","author":"Knudsen","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","article-title":"Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells","volume":"1329","author":"Filion","year":"1997","journal-title":"Biochim. Biophys. Acta (BBA) Biomembr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/08982100902792855","article-title":"Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions","volume":"19","author":"Szebeni","year":"2009","journal-title":"J. Liposome Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jconrel.2010.08.030","article-title":"Route of administration-dependent anti-inflammatory effect of liposomal alendronate","volume":"148","author":"Haber","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2217\/nnm.11.162","article-title":"Grand challenges in modulating the immune response with RNAi nanomedicines","volume":"6","author":"Goldsmith","year":"2011","journal-title":"Nanomedicine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1023\/A:1007504613351","article-title":"Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes","volume":"17","author":"Dokka","year":"2000","journal-title":"Pharm. Res."},{"key":"ref_22","first-page":"205","article-title":"Cytotoxicity evaluation of anionic nanoliposomes and nanolipoplexes prepared by the heating method without employing volatile solvents and detergents","volume":"62","author":"Mozafari","year":"2007","journal-title":"Pharmazie"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jconrel.2011.12.034","article-title":"Altering the immune response with lipid-based nanoparticles","volume":"161","author":"Peer","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tiv.2016.08.002","article-title":"In vitro toxicity of cationic micelles and liposomes in cultured human hepatocyte (HepG2) and lung epithelial (A549) cell lines","volume":"36","author":"Roursgaard","year":"2016","journal-title":"Toxicol. In Vitro"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39858","DOI":"10.1074\/jbc.M302232200","article-title":"The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection","volume":"278","author":"Simberg","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0005-2760(97)00169-0","article-title":"Effect of serum components on the physico-chemical properties of cationic lipid\/oligonucleotide complexes and on their interactions with cells","volume":"1390","author":"Zelphati","year":"1998","journal-title":"Biochim. Biophys. Acta (BBA) Lipids Lipid Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1164\/ajrccm.152.3.7545058","article-title":"Expression and distribution of cell-membrane complement regulatory glycoproteins along the human respiratory tract","volume":"152","author":"Varsano","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00128-2","article-title":"Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo","volume":"32","author":"Cullis","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1146\/annurev.biochem.68.1.611","article-title":"In vitro selection of functional nucleic acids","volume":"68","author":"Wilson","year":"1999","journal-title":"Annu. Rev. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S1748-0132(07)70083-X","article-title":"Targeted nanoparticles for cancer therapy","volume":"2","author":"Gu","year":"2007","journal-title":"Nanotoday"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17356","DOI":"10.1073\/pnas.0809154105","article-title":"Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles","volume":"105","author":"Dhar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.addr.2004.02.014","article-title":"Nanoparticle and targeted systems for cancer therapy","volume":"56","author":"Blanchette","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.12-7-864","article-title":"Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events","volume":"12","author":"Weber","year":"2007","journal-title":"Oncologist"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri2744","article-title":"Monoclonal antibodies: Versatile platforms for cancer immunotherapy","volume":"10","author":"Weiner","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1021\/nn3010476","article-title":"Targeting cancer cells: Controlling the binding and internalization of antibody-functionalized capsules","volume":"6","author":"Johnston","year":"2012","journal-title":"ACS Nano"},{"key":"ref_37","first-page":"363","article-title":"Identification of cancer targets and therapeutics using phage display","volume":"9","author":"Brissette","year":"2006","journal-title":"Curr. Opin. Drug Discov. Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1158\/0008-5472.CAN-05-4441","article-title":"Selection of tumor-binding ligands in cancer patients with phage display libraries","volume":"66","author":"Krag","year":"2006","journal-title":"Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","article-title":"Active targeting schemes for nanoparticle systems in cancer therapeutics","volume":"60","author":"Byrne","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1039\/D1CS00525A","article-title":"Activatable molecular probes for fluorescence-guided surgery, endoscopy and tissue biopsy","volume":"51","author":"Zhang","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17268","DOI":"10.1002\/anie.202009796","article-title":"Activity-Based NIR Enzyme Fluorescent Probes for the Diagnosis of Tumors and Image-Guided Surgery","volume":"60","author":"Li","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1021\/acs.bioconjchem.1c00136","article-title":"State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET","volume":"32","author":"Chomet","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2967\/jnumed.115.167155","article-title":"Immuno-PET Imaging and Radioimmunotherapy of 64Cu-\/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model","volume":"57","author":"Song","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1158\/1078-0432.CCR-19-1157","article-title":"Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model","volume":"25","author":"Song","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1021\/bc300037w","article-title":"Comparison of 64Cu-complexing bifunctional chelators for radioimmunoconjugation: Labeling efficiency, specific activity, and in vitro\/in vivo stability","volume":"23","author":"Cooper","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"ref_46","first-page":"889","article-title":"Use of the post-insertion method for the formation of ligand-coupled liposomes","volume":"7","author":"Allen","year":"2002","journal-title":"Cell. Mol. Biol. Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1039\/C2CP42738A","article-title":"Cholesterol and POPC segmental order parameters in lipid membranes: Solid state 1H-13C NMR and MD simulation studies","volume":"15","author":"Ferreira","year":"2013","journal-title":"Phys. Chem. Chem. Phys."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1801807","DOI":"10.1002\/admi.201801807","article-title":"PEG-Lipid Post Insertion into Drug Delivery Liposomes Quantified at the Single Liposome Level","volume":"6","author":"Eliasen","year":"2019","journal-title":"Adv. Mater. Interfaces"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1049\/nbt2.12094","article-title":"The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity","volume":"16","author":"Dadpour","year":"2022","journal-title":"IET Nanobiotechnol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0304-4165(85)90174-6","article-title":"Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection","volume":"839","author":"Senior","year":"1985","journal-title":"Biochim. Biophys. Acta (BBA) Gen. Subj."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0378-5173(94)00414-Z","article-title":"Pharmacokinetics and tissue distribution of adriamycin and adriamycinol after intravenous administration of adriamycin-loaded neutral proliposomes to rats","volume":"121","author":"Lee","year":"1995","journal-title":"Int. J. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0005-2736(95)00196-4","article-title":"Serum independent liposome uptake by mouse liver","volume":"1278","author":"Liu","year":"1996","journal-title":"Biochim. Biophys. Acta (BBA) Biomembr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"114238","DOI":"10.1016\/j.addr.2022.114238","article-title":"Why nanoparticles prefer liver macrophage cell uptake in vivo","volume":"185","author":"Ngo","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"400","DOI":"10.21147\/j.issn.1000-9604.2019.02.14","article-title":"Synthesis and evaluation of 64Cu-radiolabeled NOTA-cetuximab (64Cu-NOTA-C225) for immuno-PET imaging of EGFR expression","volume":"31","author":"Xu","year":"2019","journal-title":"Chin. J. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"ref_56","first-page":"719","article-title":"Comparison of cell-labeling methods with 124I-FIAU and 64Cu-PTSM for cell tracking using chronic myelogenous leukemia cells expressing HSV1-tk and firefly luciferase","volume":"27","author":"Park","year":"2012","journal-title":"Cancer Biother. Radiopharm."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:53:35Z","timestamp":1760104415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/3\/1813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":56,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25031813"],"URL":"https:\/\/doi.org\/10.3390\/ijms25031813","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]}}}